ClinicalTrials.gg
CompletedNCT00862940Updated Sep 3, 2012Results posted

A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease

A Phase 4 interventional study of Memantine and Placebo in Alzheimer's Disease, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-09-03.

Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
277
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.

Enrollment
6th of 34
277 · median 90
Started
2005
with 3 others
Phase 4
21 of 34
none open now
Registered
20th of 34
by date
Lead sponsor
4 of 34
H. Lundbeck A/S

Among the 34 studies testing memantine in Alzheimer Disease, this one is the 6th largest by enrollment, is one of 4 that started in 2005, is one of 21 in phase 4, and was the 20th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About memantine

Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing memantine in Alzheimer Disease, or all of them as a file.
02

Study summary

Pre-clinical studies have demonstrated that memantine can decrease the neuronal toxicity associated with excessive glutamate release and calcium overload in neurons. Previous studies have shown that memantine helps to treat the symptoms of Alzheimer's Disease (AD). In AD, the rate of brain tissue loss, or atrophy, is faster than in normal aging and this seems to go hand in hand with some of the symptoms of the disease. This suggests that memantine treatment in AD could provide both symptomatic improvement and neuro-protective effects. The purpose of this study was to show whether memantine, in addition to providing symptomatic benefits, can slow the rate of brain atrophy as assessed using magnetic resonance imaging (MRI) technology.

Read the detailed description

The primary objective of this study was to evaluate the effects of memantine on the rate of brain atrophy compared to placebo in patients with AD (moderate severity) over a 1-year period. This was a multinational, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study (20 mg memantine). The study also included secondary imaging, cognitive and behavioural measures.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Memantine
  • Neuroimaging
  • MRI
  • Brain atrophy
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients at least 50 years of age with a current diagnosis of probable AD of moderate severity ( score between 12 and 20, inclusive) consistent with NINCDS-ADRDA criteria and MRI scans
  • Patients must have had a knowledgeable and reliable caregiver to accompany them to all clinic visits during the study
  • Patients were either on or off existing acetylcholinesterase inhibitor (AChEI) treatment provided that the treatment had been initiated >6 months prior to screening, had stabilised with respect to dose for >3 months, and remained fixed during the entire study. AChEI treatment could not be initiated or modified during the study

Exclusion criteria

Exclusion Criteria:

  • The patient had evidence of active disease (including recent myocardial infarction and uncompensated congestive heart failure [ II-IV])
  • The patient had evidence of any clinically significant neurodegenerative disease or neurological disorder other than AD
  • The patient was for MRI

Other protocol-defined inclusion and exclusion criteria applied.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
277 participants (actual)

Study arms

  • Experimental
    Memantine

    Drug: Memantine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 10 mg tablets twice daily

    Also known as: Ebixa®

  • DrugPlacebo

    Tablets twice daily

06

What researchers measure

Primary outcomes

  1. Total Brain Atrophy Rate Estimated Using Brain Boundary Shift Integral (BBSI)

    Measures direct changes in total brain volume per visit interval (screening to Week 4, 42, or 52 or from Week 4 to Week 42 or 52)

    Time frame: Baseline to 1 year

Secondary outcomes

  1. Changes in Total Hippocampal Volume (HCV)

    Estimated mean changes in total HCV

    Time frame: Baseline to 1 year

  2. Cognitive and Behavioural Outcomes: Controlled Oral Word Association Test (COWAT) Total Score

    Adjusted mean change from baseline on cognitive and behavioural scores. COWAT: Verbal fluency test. The patient was asked to, during 1 minute, generate as many words as possible beginning with three pre-specified letters. The total score was calculated as the sum of acceptable words generated, with higher scores indicating lower cognitive impairment

    Time frame: Baseline to 1 year

  3. Cognitive and Behavioural Outcomes: Mini Mental State Examination (MMSE) Total Score

    Adjusted mean change from baseline on cognitive and behavioural scores. MMSE: Brief, structured examination of mental status that assesses orientation, memory, attention, naming, comprehension, and praxis. The range is 0 to 30, with a lower score indicating a worse mental state

    Time frame: Baseline to 1 year

07

Results

Posted Jun 3, 2011

Participant flow

The patients were recruited from each investigator's outpatient clinic.

Participant flow — Overall Study
MilestoneMemantine 10 mg Tablets Twice DailyPlacebo Tablets Twice Daily
Started133144
Completed103114
Not completed3030
Withdrew: Adverse event1512
Withdrew: Lack of efficacy13
Withdrew: Protocol violation25
Withdrew: Withdrawal by subject46
Withdrew: Non-compliance40
Withdrew: Lost to follow-up01
Withdrew: Administrative or other reason(s)43

Outcome measures

PrimaryTotal Brain Atrophy Rate Estimated Using Brain Boundary Shift Integral (BBSI)

Measures direct changes in total brain volume per visit interval (screening to Week 4, 42, or 52 or from Week 4 to Week 42 or 52)

Time frame:
Baseline to 1 year
Reported as:
Mean · mL/year
Total Brain Atrophy Rate Estimated Using Brain Boundary Shift Integral (BBSI)
mL/yearMemantine 10 mg Tablets Twice DailyPlacebo Tablets Twice Daily
Total Brain Atrophy Rate Estimated Using Brain Boundary Shift Integral (BBSI)15.24 ± 0.9715.32 ± 0.91
Statistical analysis
  • Memantine 10 mg Tablets Twice Daily vs Placebo Tablets Twice Daily · Mixed Models Analysis · p = 0.9754 · Adjusted mean difference: -0.04 · 95% CI -2.60 to 2.52
SecondaryChanges in Total Hippocampal Volume (HCV)

Estimated mean changes in total HCV

Time frame:
Baseline to 1 year
Reported as:
Mean · mm^3/year
Changes in Total Hippocampal Volume (HCV)
mm^3/yearMemantine 10 mg Tablets Twice DailyPlacebo Tablets Twice Daily
Changes in Total Hippocampal Volume (HCV)-218 ± 182-220 ± 171
Statistical analysis
  • Memantine 10 mg Tablets Twice Daily vs Placebo Tablets Twice Daily · MMRM · p = 0.842 · Adjusted mean difference: -3.50 · 95% CI -38.04 to 31.04
SecondaryCognitive and Behavioural Outcomes: Controlled Oral Word Association Test (COWAT) Total Score

Adjusted mean change from baseline on cognitive and behavioural scores. COWAT: Verbal fluency test. The patient was asked to, during 1 minute, generate as many words as possible beginning with three pre-specified letters. The total score was calculated as the sum of acceptable words generated, with higher scores indicating lower cognitive impairment

Time frame:
Baseline to 1 year
Reported as:
Least squares mean · Scale scores
Cognitive and Behavioural Outcomes: Controlled Oral Word Association Test (COWAT) Total Score
Scale scoresMemantine 10 mg Tablets Twice DailyPlacebo Tablets Twice Daily
Cognitive and Behavioural Outcomes: Controlled Oral Word Association Test (COWAT) Total Score0.78 ± 0.71-0.90 ± 0.69
Statistical analysis
  • Memantine 10 mg Tablets Twice Daily vs Placebo Tablets Twice Daily · MMRM · p = 0.034 (The p-value represents the difference from placebo for COWAT at Week 52 (MMRM).) · Mean difference (final values): 1.68 · 95% CI 0.13 to 3.23
SecondaryCognitive and Behavioural Outcomes: Mini Mental State Examination (MMSE) Total Score

Adjusted mean change from baseline on cognitive and behavioural scores. MMSE: Brief, structured examination of mental status that assesses orientation, memory, attention, naming, comprehension, and praxis. The range is 0 to 30, with a lower score indicating a worse mental state

Time frame:
Baseline to 1 year
Reported as:
Least squares mean · Scale scores
Cognitive and Behavioural Outcomes: Mini Mental State Examination (MMSE) Total Score
Scale scoresMemantine 10 mg Tablets Twice DailyPlacebo Tablets Twice Daily
Cognitive and Behavioural Outcomes: Mini Mental State Examination (MMSE) Total Score-0.50 ± 0.45-0.74 ± 0.44
Statistical analysis
  • Memantine 10 mg Tablets Twice Daily vs Placebo Tablets Twice Daily · MMRM · p = 0.602 (The p-value represents the difference from placebo for MMSE at Week 52 (MMRM).) · Mean difference (final values): 0.24 · 95% CI -0.67 to 1.15

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Memantine 10 mg Tablets Twice Daily—17/133 (12.8%)46/133 (34.6%)
Placebo Tablets Twice Daily—20/144 (13.9%)36/144 (25%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventMemantine 10 mg Tablets Twice DailyPlacebo Tablets Twice Daily
FallInjury, poisoning and procedural complications4/1338/144
Atrial fibrillationCardiac disorders3/1330/144
Femoral neck fractureInjury, poisoning and procedural complications0/1333/144
HypotensionVascular disorders0/1332/144
Abnormal behaviourPsychiatric disorders1/1330/144
AgitationPsychiatric disorders1/1331/144
AnaemiaBlood and lymphatic system disorders1/1330/144
Ankle fractureInjury, poisoning and procedural complications1/1330/144
Balance disorderNervous system disorders1/1330/144
Cardiac failureCardiac disorders1/1330/144
Most frequent other events
Most frequent other events
EventMemantine 10 mg Tablets Twice DailyPlacebo Tablets Twice Daily
DizzinessNervous system disorders11/1334/144
DiarrhoeaGastrointestinal disorders4/13310/144
HeadacheNervous system disorders9/1337/144
FallInjury, poisoning and procedural complications8/1339/144
AgitationPsychiatric disorders7/1331/144
Urinary tract infectionInfections and infestations7/1335/144

Baseline characteristics

Age Continuous
Age Continuous(years)Memantine 10 mg Tablets Twice DailyPlacebo Tablets Twice DailyTotal
Mean73.7 ± 8.874.4 ± 7.774.1 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Memantine 10 mg Tablets Twice DailyPlacebo Tablets Twice DailyTotal
Female8375158
Male5069119
Controlled Oral Word Association Test (COWAT): Baseline Efficacy Scores
Controlled Oral Word Association Test (COWAT): Baseline Efficacy Scores(Number of words)Memantine 10 mg Tablets Twice DailyPlacebo Tablets Twice DailyTotal
Mean19.7 ± 10.319.2 ± 8.819.4 ± 9.6
Category Fluency Test (CFT): Baseline Efficacy Scores
Category Fluency Test (CFT): Baseline Efficacy Scores(Number of words)Memantine 10 mg Tablets Twice DailyPlacebo Tablets Twice DailyTotal
Mean13.5 ± 5.813.3 ± 5.913.4 ± 5.9
ADAS-cog-Orientation Test (ADAS-cog-OT): Baseline Efficacy Scores
ADAS-cog-Orientation Test (ADAS-cog-OT): Baseline Efficacy Scores(Points)Memantine 10 mg Tablets Twice DailyPlacebo Tablets Twice DailyTotal
Mean4.2 ± 1.64.0 ± 1.74.1 ± 1.7
Stroop Interference Test - Incongruent (SIT-I): Baseline Efficacy Scores
Stroop Interference Test - Incongruent (SIT-I): Baseline Efficacy Scores(Seconds)Memantine 10 mg Tablets Twice DailyPlacebo Tablets Twice DailyTotal
Mean170.3 ± 60.4176.4 ± 56.7173.4 ± 58.5
Stroop Interference Test - Congruent (SIT-C): Baseline Efficacy Scores
Stroop Interference Test - Congruent (SIT-C): Baseline Efficacy Scores(Seconds)Memantine 10 mg Tablets Twice DailyPlacebo Tablets Twice DailyTotal
Mean70.5 ± 49.168.8 ± 41.769.6 ± 45.4
Mini Mental State Examination (MMSE): Baseline Efficacy Scores
Mini Mental State Examination (MMSE): Baseline Efficacy Scores(Points)Memantine 10 mg Tablets Twice DailyPlacebo Tablets Twice DailyTotal
Mean16.9 ± 2.417.0 ± 2.416.9 ± 2.4

2 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Wilkinson D, Fox NC, Barkhof F, Phul R, Lemming O, Scheltens P. Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. J Alzheimers Dis. 2012;29(2):459-69. doi: 10.3233/JAD-2011-111616. PubMed 22269160 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Feb 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2009
First posted
Mar 17, 2009
Start
Sep 2005
Primary completionActual
Feb 2009
CompletionActual
Apr 2009
Results first posted
Jun 3, 2011
Last update
Sep 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00862940
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Mar 17, 2009
Start date
Sep 2005
Primary completion
Feb 2009
Completion
Apr 2009
Results posted
Jun 3, 2011
Last update
Sep 3, 2012

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion